SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
CRANBURY, N.J., Feb. 18, 2016 -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, will host a conference call and live audio webcast on Friday, February 26, 2016 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2015.
The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call at 8:00 a.m. ET by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international) participant code 52850523.
A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at http://ir.amicustherapeutics.com/events.cfm, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register and to download and install any necessary software.
A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on February 26, 2016. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); participant code 52850523.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) products for Fabry disease, Pompe disease, and other Lysosomal Storage Disorders.
FOLD-G
CONTACT: Investors/Media: Amicus Therapeutics Sara Pellegrino Senior Director, Investor Relations [email protected] (609) 662-5044
